Journals / Türk Onkoloji Dergisi / 2021 / Cilt: 36 - Sayı: 4

Concurrent Use of Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors with Palliative Radiotherapy for Metastatic Breast Cancer Patients: A Review of Toxicity

Pages
538–542
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Until then, oncologists should evaluate each case with caution regarding the potential risks of CDK 4/6 inhibitors in combination with radiotherapy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Breast cancer remains to be the most common cancer in women.
📊
Key Findings & Data:There have been improvements in the treatment of hormone-sensitive metastatic breast cancer by the addition of CDK 4/6 inhibitors to endocrine treatment.
💡
Conclusion & Impact:Until then, oncologists should evaluate each case with caution regarding the potential risks of CDK 4/6 inhibitors in combination with radiotherapy.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Breast cancer remains to be the most common cancer in women. Given the recent developments in oncology, while more women with early breast cancer are being cured, patients with metastatic breast cancer are living longer. There have been improvements in the treatment of hormone-sensitive metastatic breast cancer by the addition of CDK 4/6 inhibitors to endocrine treatment. CDK 4 and CDK 6 control entry into the cell cycle via estrogen signaling pathway and their inhibition was shown to prevent tumor cell cycle progression. Three CDK4/6 inhibitors available for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer are palbociclib, ribociclib, and abemaciclib. CDK 4/6 inhibitors are suggested as radiosensitizers given their mechanism of action that inhibits cell cycle progression as well as DNA repair. However, there are concerns regarding their concurrent use with radiotherapy given their potential to delay normal tissue repair. Currently, there are several retrospective series suggesting a site-dependent toxicity. After reviewing preclinical and retrospective studies, we suggest further studies are required to clarify the safety of this combination. Until then, oncologists should evaluate each case with caution regarding the potential risks of CDK 4/6 inhibitors in combination with radiotherapy.

🔖

Cite This Article

SÖNMEZ, Ö., TEZCANLI, E. (2022). Concurrent Use of Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors with Palliative Radiotherapy for Metastatic Breast Cancer Patients: A Review of Toxicity. Türk Onkoloji Dergisi, Cilt: 36 - Sayı: 4, 538–542. https://ajindex.com/articles/639081

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med 2016;375(20):1925–36
  2. Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol 2018;29(7):1541–7
  3. Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. MONARCH 3:Abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol 2017;35(32):3638–46
  4. Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 2009;8:547–66
  5. Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study. Lancet Oncol 2015;16(1):25–35
  6. Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormonereceptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): Final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 2016;17:425–39
  7. Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med 2018;379:1926–36
  8. Janni W, Alba E, Bachelot T, Diab S, Gil-Gil M, Beck TJ. First-line ribociclib plus letrozole in postmenopausal women with HR+, HER2-advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial. Breast Cancer Res Treat. 2018;169:469–79
  9. Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol 2018;36:2465–72. 10.Johnston S, Martin M, Leo AD, Im SA, Awada A, Forrester T. MONARCH 3 final PFS: A randomized study of abemaciclib as initial therapy for advanced breast cancer. Npj Breast Cancer 2019;5:1–8. 11.Sledge GW, Toi M, Neven P, Sohn J, Inoue K, Pivot X. MONARCH 2: Abemaciclib in combination with ful